Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium 1

3552 - First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)


08 Oct 2016


Presidential Symposium 1


Gabriel Hortobagyi


Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435


G.N. Hortobagyi1, S.M. Stemmer2, H.A. Burris3, Y.S. Yap4, G.S. Sonke5, S. Paluch-Shimon6, M. Campone7, K. Blackwell8, F. André9, E.P. Winer10, W. Janni11, S. Verma12, P. Conte13, C.L. Arteaga14, D. Cameron15, F. Xuan16, F. Souami17, M. Miller16, C. Germa16, J. O'Shaughnessy18

Author affiliations

  • 1 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv/IL
  • 3 Drug Development Unit, Sarah Cannon Research Institute, Nashville/US
  • 4 Division Of Medical Oncology, National Cancer Center, Singapore/SG
  • 5 Department Of Medical Oncology, Netherlands Cancer Institute and BOOG Study Center, Amsterdam/NL
  • 6 The Oncology Institute, Sheba Medical Center, Ramat Gan/IL
  • 7 Institut De Cancérologie De L’ouest, René Gauducheau, Saint-Herblain/FR
  • 8 Department Of Medicine, Duke University Medical Center, Durham/US
  • 9 Department Of Medical Oncology, Institut Gustave Roussy, Université Paris Sud, 94800 - Villejuif/FR
  • 10 Breast Oncology Center, Dana-Farber Cancer Institute, Boston/US
  • 11 Department Of Gynecology And Obstetrics, University of Ulm, Ulm/DE
  • 12 Department Of Oncology, Tom Baker Cancer Centre, Calgary/CA
  • 13 University Of Padova, Istituto Oncologico Veneto IRCCS, Padova/IT
  • 14 Center For Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, Nashville/US
  • 15 Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh/GB
  • 16 Oncology, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 17 Oncology, Novartis Pharma AG, Basel/CH
  • 18 Texas Oncology-baylor Charles A. Sammons Cancer Center, The US Oncology Network, Dallas/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3552


Endocrine therapy (ET) is an established first-line treatment for ABC. However, ET resistance and disease progression eventually occur in most patients. Cyclin-dependent kinase (CDK) 4/6 inhibition is a valid treatment strategy for HR+ ABC and may help overcome or delay ET resistance. Here we report interim results from MONALEESA-2 (NCT01958021), a double-blind, randomized, phase 3 trial evaluating the efficacy and safety of first-line ribociclib (a selective CDK4/6 inhibitor) + letrozole in women with HR + , HER2– ABC.


Postmenopausal women (N = 668) with HR + , HER2– ABC with no prior systemic treatment for ABC were randomized (1:1) to receive ribociclib (600 mg/day, 3-weeks-on/1-week-off) + letrozole (2.5 mg/day, continuous) or placebo + letrozole. The primary endpoint was locally assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS; key secondary endpoint), overall response rate (ORR), clinical benefit rate (CBR), and safety. A pre-planned interim analysis was conducted after 243 PFS events (information fraction 80%) had occurred.


Baseline patient characteristics were balanced between treatment arms. The study met its primary objective: at the interim analysis (data cut-off Jan 29, 2016), PFS was significantly improved in the ribociclib arm, with a hazard ratio of 0.556 (95% CI: 0.429–0.720; p = 0.00000329). Median PFS was not reached in the ribociclib arm (95% CI: 19.3–not estimable) vs 14.7 months in the placebo arm (95% CI: 13.0–16.5). In patients with measurable disease at baseline, ORR was 53% vs 37% (ribociclib vs placebo arm; p = 0.00028) and CBR was 80% vs 72% (p = 0.02). Common Grade 3/4 adverse events (≥5% of patients; ribociclib vs placebo arm) were neutropenia (59% vs 1%), leukopenia (21% vs 1%), hypertension (10% vs 11%), elevated alanine aminotransferase (9% vs 1%), lymphopenia (7% vs 1%), and elevated aspartate aminotransferase (6% vs 1%). OS data were immature at data cut-off.


Ribociclib + letrozole was well tolerated and significantly prolonged PFS vs letrozole alone in postmenopausal women with HR + , HER2– ABC who had received no prior therapy for ABC.

Clinical trial identification


Legal entity responsible for the study

Novartis Pharmaceuticals Corporation


Novartis Pharmaceuticals Corporation


G.N. Hortobagyi: Grants and personal fees from Novartis, during the conduct of the study; personal fees from Eli Lilly, LLC, and Pfizer, outside the submitted work. S.M. Stemmer: Advisory boards for Novartis in Hong Kong, Germany and Berlin (June 2016); PI in pharma sponsored trials; travel and hotel expenses for Genomic Health. Y.S. Yap: Consultant/advisory board and honoraria from Novartis. S. Paluch-Shimon: Payment schedule for study costs from Sheba Medical Center, during the conduct of the study; personal fees from Novartis and Roche, consultancy and personal fees from Pfizer, outside the submitted work. M. Campone: Advisory board, grant, and speaker bureau for Novartis; Advisory board for Menarini and Roche; Advisory board speaker bureau for AstraZeneca and Pfizer. K. Blackwell: Institute research support and consultancy fees from Novartis. F. André: Research support from Novartis. W. Janni: Research grants and honoraria from Novartis. S. Verma: Advisory boards for Amgen, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche. P. Conte: Speaker and advisory boards for AstraZeneca, Celgene, Eli Lilly, Novartis, Obi, and Roche; research grants from Merck-Serono, Novartis, and Roche. C.L. Arteaga: Consultant for AstraZeneca, Clovis, Kiyatek, Lilly, Merrimak, Monogram Bio, Novartis, Provista, Radius, Roche, Susan G. Komen, Symphogen; grants from AstraZeneca, Novartis, PUMA Biotechnology, Symphogen, U3 Pharma-Daichi; stock ownership at Provista. D. Cameron: Institute remuneration for advisory boards for Novartis and Pfizer, and DMC for Lilly. F. Xuan, M. Miller, C. Germa: Employee of Novartis; stock ownership at Novartis. F. Souami: Employee of Novartis. J. O'Shaughnessy: Advisor and honorarium from Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings